| Version |
2.5 |
| Creation Date |
2005-06-13 13:24:05 |
| Update Date |
2009-06-23 18:06:55 |
| Primary Accession Number |
DB00375 |
| Secondary Accession Number |
|
| Name |
Colestipol |
| Drug Type |
|
| Description |
Highly crosslinked and insoluble basic anion exchange resin used as anticholesteremic. It may also may reduce triglyceride levels. [PubChem] |
| Synonyms |
- Colestipolum [INN-Latin]
|
| Brand Names |
- Cholestabyl
- Colestid
|
| Brand Mixtures |
Not Available |
| Chemical IUPAC Name |
N'-(2-aminoethyl)-N-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine; 2-(chloromethyl)oxirane |
| Chemical Formula |
C11H28ClN5O |
| Chemical Structure |
 |
| CAS Registry Number |
50925-79-6 |
| InChI Identifier |
InChI=1/C8H23N5.C3H5ClO/c9-1-3-11-5-7-13-8-6-12-4-2-10;4-1-3-2-5-3/h11-13H,1-10H2;3H,1-2H2 |
| InChI Key |
GMRWGQCZJGVHKL-UHFFFAOYAD |
| KEGG Drug |
Not Available |
| KEGG Compound |
C06925  |
| PubChem Compound |
62816 |
| PubChem Substance |
429654 |
| ChEBI ID |
Not Available |
| PharmGKB ID |
PA449096 |
| HET ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
00642975 |
| RxList Link |
http://www.rxlist.com/cgi/generic/colestipol.htm |
| PDRhealth Link |
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/col1094.shtml |
| Wikipedia Link |
http://en.wikipedia.org/wiki/Colestipol |
| FDA Label |
Not Available |
| Material Safety Data Sheet (MSDS) |
|
| Synthesis Reference |
Not Available |
| Average Molecular Weight |
281.8260 |
| Monoisotopic Molecular Weight |
281.1982 |
| State |
Solid |
| Melting Point |
Not Available |
| Experimental Water Solubility |
Insoluble
Source: PhysProp
|
| Predicted Water Solubility |
Not Available
Calculated using ALOGPS
|
| Experimental LogP/Hydrophobicity |
-2.206
Source: PhysProp
|
| Predicted LogP |
Not Available
Calculated using ALOGPS
|
| Experimental LogS |
Not Available |
| Predicted LogS |
Not Available
Calculated using ALOGPS
|
| Experimental Caco2 Permeability |
Not Available |
| pKa/Isoelectric Point |
Not Available |
| Mass Spectrum |
Not Available
|
| MOL File |
Show | Download |
| SDF File |
Show | Download |
| PDB File |
Show | Download |
| 2D Structure |
|
| 3D Structure |
|
| Experimental PDB ID |
Not Available |
| Isomeric SMILES |
ClC[C@@H]1CO1.NCCNCCNCCNCCN |
| Canonical SMILES |
ClCC1CO1.NCCNCCNCCNCCN |
| Drug Category |
- Anion Exchange Resins
- Antilipemic Agents
|
| ATC Codes |
|
| AHFS Codes |
|
| Indication |
For use, as adjunctive therapy to diet, for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. |
| Pharmacology |
Cholesterol is the major, and probably the sole precursor of bile acids. During normal digestion, bile acids are secreted via the bile from the liver and gall bladder into the intestines. Bile acids emulsify the fat and lipid materials present in food, thus facilitating absorption. A major portion of the bile acids secreted is reabsorbed from the intestines and returned via the portal circulation to the liver, thus completing the enterohepatic cycle. Only very small amounts of bile acids are found in normal serum. Colestipol hydrochloride binds bile acids in the intestine forming a complex that is excreted in the feces. This nonsystemic action results in a partial removal of the bile acids from the enterohepatic circulation, preventing their reabsorption. Since colestipol hydrochloride is an anion exchange resin, the chloride anions of the resin can be replaced by other anions, usually those with a greater affinity for the resin than the chloride ion. |
| Mechanism of Action |
Colestipol is a non-absorbed, lipid-lowering polymer that binds bile acids in the intestine, impeding their reabsorption. As the bile acid pool becomes depleted, the hepatic enzyme, cholesterol 7-(alpha)-hydroxylase, is upregulated, which increases the conversion of cholesterol to bile acids. This causes an increased demand for cholesterol in the liver cells, resulting in the dual effect of increasing transcription and activity of the cholesterol biosynthetic enzyme, hydroxymethyl-glutaryl-coenzyme A (HMG-CoA) reductase, and increasing the number of hepatic low-density lipoprotein (LDL) receptors. These compensatory effects result in increased clearance of LDL cholesterol (LDL-C) from the blood, resulting in decreased serum LDL-C levels. Serum triglyceride levels may increase or remain unchanged. The end result is increased clearance of LDL-cholesterol from the blood with decreased serum LDL-cholesterol. |
| Absorption |
Not absorbed from the gastrointestinal tract. |
| Toxicity |
Oral LD50 in rats is > 1000 mg/kg. Symptoms of overdose may include eye irritation, constipation, abdominal cramps, nausea, vomiting, diarrhea, and hypersensitivity. However, as colestipol is not absorbed, the risk of systemic toxicity is low. |
| Protein Binding |
Not applicable (not hydrolyzed by digestive enzymes and not absorbed). |
| Biotransformation |
Not applicable (not hydrolyzed by digestive enzymes and not absorbed). |
| Half Life |
Not Available |
| Dosage Forms |
| Form |
Route |
| Granule |
Oral |
| Tablet |
Oral |
|
| Patient Information |
Show |
| Contraindications |
Show |
| Interactions |
Show |
| Drug Interactions |
| Drug |
Interaction |
| Acenocoumarol |
The gastro-intestinal binding agent decreases the anticoagulant effect |
| Anisindione |
The gastro-intestinal binding agent decreases the anticoagulant effect |
| Dicumarol |
The gastro-intestinal binding agent decreases the anticoagulant effect |
| Digoxin |
The resin decreases the effect of digoxin |
| Fluvastatin |
Increased/decreased effect according to spacing |
| Hydrocortisone |
Cholestyramine decreases the effect of hydrocortisone |
| Levothyroxine |
The resin decreases the absorption of thyroid hormones |
| Liothyronine |
The resin decreases the absorption of thyroid hormones |
| Liotrix |
The resin decreases the absorption of the thyroid hormones |
| Raloxifene |
The resin decreases the effect of raloxifene |
| Thyroglobulin |
The resin decreases the absorption of the thyroid hormones |
| Ursodeoxycholic acid |
The resin decreases the effect of ursodiol |
| Warfarin |
The gastro-intestinal binding agent decreases the anticoagulant effect |
|
| Food Interactions |
|
| Pathways |
Not Available
|
| General References |
- Wikipedia
- RxList
- PDRhealth
|
| Organisms Affected |
|
